MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, has regained compliance with the Nasdaq Capital Market's market value of listed securities (MVLS) requirement. The company received confirmation from NASDAQ on July 23, 2024, that it has satisfied the MVLS requirement as outlined in Nasdaq Listing Rule 5550(b)(2). This development ensures MiNK Therapeutics' continued listing on the NASDAQ Capital Market, and the matter is now considered closed.
MiNK Therapeutics, Inc. (NASDAQ: INKT), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di therapie cellulari allogeneiche, pronte all'uso, a base di cellule T naturale invarianti (iNKT) per il cancro e le malattie mediate dal sistema immunitario, ha riacquistato la conformità con il requisito del valore di mercato dei titoli quotati (MVLS) del Nasdaq Capital Market. L'azienda ha ricevuto conferma da NASDAQ il 23 luglio 2024, di aver soddisfatto il requisito MVLS come delineato nella Nasdaq Listing Rule 5550(b)(2). Questo sviluppo assicura il continuo mantenimento della registrazione di MiNK Therapeutics sul NASDAQ Capital Market, e la questione è ora considerata chiusa.
MiNK Therapeutics, Inc. (NASDAQ: INKT), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de terapias celulares alogénicas, listas para usar, de células T naturales invariantes (iNKT) para el cáncer y enfermedades mediadas por el sistema inmunológico, ha recuperado el cumplimiento con el requisito de valor de mercado de valores listados (MVLS) del Nasdaq Capital Market. La empresa recibió confirmación de NASDAQ el 23 de julio de 2024, de que ha cumplido con el requisito de MVLS según lo descrito en la Nasdaq Listing Rule 5550(b)(2). Este desarrollo asegura la continuidad de la cotización de MiNK Therapeutics en el NASDAQ Capital Market, y el asunto ahora se considera cerrado.
MiNK Therapeutics, Inc. (NASDAQ: INKT)는 암과 면역 매개 질환을 위한 동종 이식, 즉시 사용 가능한 불변 자연 살해 T (iNKT) 세포 치료법 개발에 주력하는 임상 단계의 생명공학 회사로, Nasdaq 자본 시장의 상장 증권의 시장 가치 요구 조건 (MVLS)을 재충족했습니다. 이 회사는 2024년 7월 23일 NASDAQ으로부터 MVLS 요구 사항을 충족했다는 확인을 받았습니다. 이는 Nasdaq Listing Rule 5550(b)(2)에 요약되어 있습니다. 이러한 발전은 MiNK Therapeutics의 NASDAQ 자본 시장에서의 지속적인 상장을 보장하며, 이 문제는 이제 종결된 것으로 간주됩니다.
MiNK Therapeutics, Inc. (NASDAQ: INKT), une entreprise biopharmaceutique en phase clinique axée sur le développement de thérapies cellulaires allogéniques, prêtes à l'emploi, à base de cellules T naturelles invariantes (iNKT) pour le cancer et les maladies immunitaires, a récupéré sa conformité avec l'exigence de valeur de marché des titres cotés (MVLS) du Nasdaq Capital Market. L'entreprise a reçu la confirmation de NASDAQ le 23 juillet 2024, qu'elle a satisfait à l'exigence MVLS comme l'indique la règle d'inscription Nasdaq 5550(b)(2). Ce développement garantit la poursuite de l'inscription de MiNK Therapeutics sur le NASDAQ Capital Market, et la question est désormais considérée comme close.
MiNK Therapeutics, Inc. (NASDAQ: INKT), ein biopharmazeutisches Unternehmen in klinischen Phasen, das sich auf die Entwicklung von allogenen, einsatzbereiten, invarianten natürlichen Killer-T-Zelltherapien (iNKT) für Krebs und immunvermittelte Krankheiten spezialisiert hat, hat die Konformität mit den Anforderungen des Nasdaq Capital Market bezüglich des Marktwerts von notierten Wertpapieren (MVLS) wiedererlangt. Das Unternehmen erhielt am 23. Juli 2024 von NASDAQ die Bestätigung, dass es die MVLS-Anforderung gemäß der Nasdaq Listing Rule 5550(b)(2) erfüllt hat. Diese Entwicklung sichert die fortgesetzte Zulassung von MiNK Therapeutics im Nasdaq Capital Market, und das Thema wird nun als abgeschlossen betrachtet.
- Regained compliance with Nasdaq Capital Market's MVLS requirement
- Secured continued listing on the NASDAQ Capital Market
- None.
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced today that it has regained compliance with the Nasdaq Capital Market’s market value of listed securities (“MVLS”) requirement.
On July 23, 2024, MiNK received notice from NASDAQ confirming that the Company has satisfied the MVLS requirement as set forth in Nasdaq Listing Rule 5550(b)(2). Accordingly, the Company now satisfies the MVLS requirement for continued listing on the NASDAQ Capital Market and the matter is now closed.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
Investor Contact
917-362-1370
Media Contact
781-674-4428
communications@minktherapeutics.com
FAQ
What did MiNK Therapeutics (INKT) announce on July 31, 2024?
When did MiNK Therapeutics (INKT) receive notice of compliance from NASDAQ?
What is the significance of MiNK Therapeutics (INKT) regaining NASDAQ compliance?
What type of therapies is MiNK Therapeutics (INKT) developing?
